Galapagos NV

Galapagos NV is a clinical stage biotech company focused on developing novel mode-of-action medicines. Headquartered in Belgium, the company employs 400 people and reported 2013 revenues of €160M. Galapagos' most advanced candidate drug GLPG0634 shows excellent safety and efficacy in rheumatoid arthritis patients and is fully proprietary to the company. With GLPG0634, Galapagos demonstrates its capabilities in developing novel medicines for difficult-to-cure diseases.